Dermatology & Cosmetics

An active either changes skin biology or it does not, and a claims file has to show which. GenXMap turns explant and microbiome data into the statistical evidence a claim rests on, with the methods written down well enough to be re-run by someone else.

The Claims Substantiation Package

Built for the moment a claim has to hold up: it establishes whether an active changes treated skin, which pathways the change falls into, and whether the effect survives donor variability.

• Differential expression on treated versus untreated skin, with the effect size stated
• Pathway enrichment, so the change is attributed to biology and not to a gene list
• Donor variability tested explicitly, to separate a real effect from one donor carrying it
• Iteration comparison, to tell two formulations apart by more than noise

We are not a service provider taking an order and running a protocol. The design is ours: how many donors the design needs before an effect can be told from donor variability at all — a question that has to be settled before sampling, not after. That is what an R&D team working on the subject brings, and it is the difference between buying an analysis and running a programme.

The questions we take on

• Whether an active changes the transcriptome of treated skin, and by how much
• Which biological pathways the change actually falls into
• Whether the effect holds across donors, or rides on one of them
• Whether two formulation iterations differ by more than noise

How the analysis runs

Working under claims scrutiny

A dermo-cosmetic claim is read by people who did not run the study. Every report carries the exact tool versions, parameters and thresholds used, so the analysis can be audited or reproduced.

Formulation programmes run in cycles. The pipeline is versioned and held fixed across a series, which is the only way a comparison between iterations means anything.

What the report contains

Methods with exact tool versions, parameters and thresholds. QC and cohort-level figures. Statistical results. An interpretation written against the biological question you started from.

Built to be audited or reproduced by a third party.

When the active works through extracellular vesicles

A dermo-cosmetic active that modulates cell communication rather than a single pathway leaves its trace in the vesicles cells release, not only in their own transcriptome. Reading that requires isolating the vesicles, sizing and counting them, and analysing their cargo — three steps, and the first two need instruments worth reaching for rather than duplicating.

The Exosome Characterization Platform is built for exactly that: OMICS4’s isolation and cargo-analysis capacity combined with the specialised nanoparticle-characterization equipment of the Faculté de Pharmacie de Marseille, for higher-resolution sizing, counting and marker validation than either partner reaches alone. The vesicle cargo is then read alongside the transcriptome of the cells that released it, which is where a claim on cell communication becomes defensible.

See the Exosome Characterization Platform

Where the data comes from

The laboratory work behind these analyses runs on OMICS4, GenXMap’s platform site. Sample requirements, shipping and turnaround are published there.

We also take on data we did not generate. An existing dataset, from an earlier study or from another provider, is analysed on its own terms. What decides the work is the question and the metadata that comes with it, not who ran the sequencer.

Book the platforms on OMICS4